Carsten Nieder

TL;DR: The present literature survey aims at clarification of the role of radiotherapy in combined modality settings by identification of dose-response relationships, predictive factors for local control, and potential pitfalls in the interpretation of retrospective studies.

TL;DR: The number of published reirradiation studies has increased in recent years, and many studies examined highly conformal and precise radiotherapy, in particular of brain and head and neck tumours.

TL;DR: The success of selective dose escalation depends on correct staging and target volume identification, which can be improved by biological imaging, and identification of biologically relevant subvolumes, which determine tumor control as mentioned in this paper.

TL;DR: The integration of the oral cytotoxic agent temozolomide into current treatment protocols of postoperative combination therapy with radiation and drugs is discussed, especially in the context of the recently published randomized trial of the EORTC/NCIC, which showed that radiotherapy plus concomitant and adjuvant temozoomide significantly improved progression-free and overall survival over radiotherapy alone.

TL;DR: It remains unclear whether the apparent influence of p53 status on outcome in non-Hodgkin's lymphoma is independent of established parameters such as stage, performance status, etc.